Fibronostics is proud to announce today that it has secured $6.5 million in funding. In addition – Sven Henrichwark, PhD, has been named the company’s new CEO.
NEW YORK and SINGAPORE, June 15, 2022 /PRNewswire/ — Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to the financing, Sven Henrichwark, PhD, […]
Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL).
Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL).
AASLD Poster: Comparing Non-Invasive Tools – LIVERFASt™, FIB-4 and Transient Elastography in Sequential and Combinatory Pathways for NAFLD.
The main endpoints were the comparative diagnostic values of LF-Fib in NAFLD pts with or without T2DM for cirrhosis (F4) and severe fibrosis (F3F4) using liver stiffness measurements (LSM M/XL), […]
AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.
AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.
ADA 2021: LIVERFAStTM Has Similar Performance to Liver Biopsy for the Screening of NASH Fibrosis in Type 2 Diabetes Mellitus (T2D).
Fibronostics_ADA-2021
EASL Poster: Noninvasive LIVERFASt transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients.
2021_EASL_ePOSTER_Transition-to-Fibrosis-vf-submitted
Fibronostics is proud to partner with the American Liver Foundation to bring you an easy screening tool for fatty liver disease.
Fibronostics have partnered with the American Liver Foundation to bring you an easy screening tool for fatty liver disease. You can take ALF’s new #ThinkLiverThinkLife quiz to see whether you or […]
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut eleifend, ante quis blandit aliquet
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut eleifend, ante quis blandit aliquet, turpis augue tincidunt enim, et placerat nisi tellus sed ligula. Pellentesque habitant morbi tristique senectus et […]
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut eleifend, ante quis blandit aliquet
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut eleifend, ante quis blandit aliquet, turpis augue tincidunt enim, et placerat nisi tellus sed ligula. Pellentesque habitant morbi tristique senectus et […]
Fibronostics Secures Financing, Announces New CEO
Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to the financing, Sven Henrichwark, PhD, has been named the […]
